Background and Purpose-MAGL (monoacylglycerol lipase) is an enzyme that hydrolyzes the endocannabinoid 2-arachidonoylglycerol and regulates the production of arachidonic acid and prostaglandins-substances that mediate tissue inflammatory response. Here, we have studied the effects of the selective MAGL inhibitors JZL184 and MJN110 and their underlying molecular mechanisms on 3 different experimental models of focal cerebral ischemia. Methods-SHR (spontaneously hypertensive rats) and normotensive WKY (Wistar Kyoto) rats were subject to an intracortical injection of the potent vasoconstrictor endothelin-1, permanent occlusion of a distal segment of the middle cerebral artery via craniectomy, or transient occlusion of the middle cerebral artery by the intraluminal suture method. JZL184 or MJN110 was administered 60 minutes after focal cerebral ischemia. Infarct volumes, hemispheric swelling, and functional outcomes were assessed between days 1 to 28 by magnetic resonance imaging, histology, and behavioral tests. Results-Pharmacological inhibition of MAGL significantly attenuated infarct volume and hemispheric swelling. MAGL inhibition also ameliorated sensorimotor deficits, suppressed inflammatory response, and decreased the number of degenerating neurons. These beneficial effects of MAGL inhibition were not fully abrogated by selective antagonists of cannabinoid receptors, indicating that the anti-inflammatory effects are caused by inhibition of eicosanoid production rather than by activation of cannabinoid receptors. Conclusions-Our results suggest that MAGL may contribute to the pathophysiology of focal cerebral ischemia and is thus a promising therapeutic target for the treatment of ischemic stroke. Visual Overview-An online visual overview is available for this article. T he endocannabinoid system, comprising the cannabinoid receptors 1 and 2 (CB1 and CB2) their lipid ligands 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide, and enzymes responsible for the biosynthesis and degradation of ligands have become a subject of great interest in neuropharmacology because of their predominant distribution in both central and peripheral nervous systems and for their capacity to play a modulating role in diverse physiological processes.
T he endocannabinoid system, comprising the cannabinoid receptors 1 and 2 (CB1 and CB2) their lipid ligands 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide, and enzymes responsible for the biosynthesis and degradation of ligands have become a subject of great interest in neuropharmacology because of their predominant distribution in both central and peripheral nervous systems and for their capacity to play a modulating role in diverse physiological processes. 1 Investigation of the endocannabinoid system has also provided new insight into the underlying pathological mechanisms of various acute and chronic neurological disorders. 2, 3 There is convincing evidence that the components of endocannabinoid system are altered during ischemic stroke in both animals and humans, [4] [5] [6] [7] [8] [9] indicating that this system may contribute to the consequences of cerebral ischemia via multiple mechanisms. Although numerous studies have examined the role of the endocannabinoid system in experimental models of ischemic stroke during the past decade, 10 results have been rather conflicting in supporting either a beneficial or a detrimental role. Nevertheless, a recent systematic review and meta-analysis reported that cannabinoids significantly reduce infarct volume and improve functional outcome in several experimental models of cerebral ischemia. 11 In particular, Nomura et al 12 provided compelling evidence that the endocannabinoid and eicosanoid systems are metabolically coupled through the action of MAGL (monoacylglycerol lipase)-the enzyme that hydrolyzes 2-AG to arachidonic acid for eicosanoid biosynthesis. Pharmacological inhibition of MAGL resulted in a robust increase of the brain 2-AG levels and a concomitant reduction of arachidonic acid and downstream inflammatory eicosanoid metabolites. Although the therapeutic potential of compounds targeting the endocannabinoid system has been investigated, the effects of MAGL inhibition and the mechanisms of action in cerebral
Neuroprotective Effects of MAGL (Monoacylglycerol Lipase)
Inhibitors in Experimental Ischemic Stroke ischemia are still unclear. In the present study, we investigated the effects of 2 potent and selective MAGL inhibitors in 3 rat models of ischemic stroke.
Materials and Methods
All materials, methods, and data obtained for the current study are available from the corresponding author on request. Detailed materials and procedures are described in the online-only Data Supplement.
Animals
Experiments were performed in adult male SHR (spontaneously hypertensive rats) and normotensive WKY (Wistar Kyoto) rats, weighing 270 to 300 g (Harland Laboratories, Frederick, MD). Animals were kept in a room with controlled temperature and a 12-hour light/dark cycle and fed with standard food and water. SHR were selected to include chronic hypertension as a common comorbidity factor in clinical stroke, according to the recommendations of the modified Stroke Therapy Academic Industry Roundtable criteria. 13 All animal care and experimental procedures were performed in accordance with the National Institutes of Health guidelines and with an approved protocol from the National Institute of Neurological Disorders and Stroke Animal Care and Use Committee.
Induction of Cerebral Ischemia
Three different experimental models of ischemia were used, in which cerebral ischemia was caused by either an intracortical injection of the potent vasoconstrictor endothelin-1 (ET-1); by permanent cauterization of a distal branch of the middle cerebral artery (MCA) 14 or by the standard transient MCA occlusion (tMCAO) using an intraluminal suture followed by reperfusion.
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Pharmacological Treatments
All groups were performed and quantified in a randomized fashion by investigators blinded to specific treatment. Rats received an intraperitoneal administration of either JZL184 or MJN110 60 minutes after stroke induction. An additional set of animals received an intraperitoneal injection of either AM251 or AM630 30 minutes after stroke induction. Routes and dose of administration for each compound were chosen based on previous studies. [16] [17] [18] 
Magnetic Resonance Imaging
Magnetic resonance imaging was performed 24 hours after induction of stroke on a 7 T/30 cm AVIII MRI system (Bruker Biospin, Inc, Billerica, MA) under inhalation anesthesia as described previously.
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Assessment of Functional Outcome
Functional outcome was evaluated as described previously 15, [20] [21] [22] and in the online-only Data supplement.
Histology and Immunohistochemistry
Coronal brain sections (30 μm) were processed 1, 3, or 7 days after ischemic stroke, immunofluorescence, and confocal microscopy were performed as described in the online-only Data Supplement.
Profiling of Local Cytokine Expression
Local cytokine expression was performed using the rat cytokine ELISA plate array kit (Signosis, Santa Clara, CA).
RNA Extraction and Real-Time Polymerase Chain Reaction
Gene expression analysis was performed using the TaqMan Assays (Applied Biosystems).
Statistics
The statistical methods are presented in the online-only Data Supplement.
Results
MAGL Inhibitor JZL184 Reduces Infarct Volume and Improves Functional Outcome in the ET-1 Model
To investigate the MAGL inhibitor JZL184 for its therapeutic potential in animal models of stroke, we first used the ET-1 model of focal ischemia. The ET-1 model was initially optimized in both SHR and WKY rats using an intracerebral injection of ET-1 into the right somatosensory cortex. This injection led to a significant and stable reduction of cerebral blood flow (CBF; to ≈30% of baseline) for 3 hours and resulted in extensive infarcts in both cortical and subcortical areas, including primary and secondary somatosensory cortex, primary motor cortex, the underlying white matter, and a small region of dorsolateral striatum, as estimated by T2-weighted magnetic resonance imaging and confirmed postmortem using Nissl staining ( Figure 1B Figure 1B ). JZL184 also significantly attenuated brain swelling in SHR versus vehicletreated animals (P<0.01), but the decrease in brain swelling in WKY was not significant (P>0.05; Figure 1B ). The levels of 2-AG and N-arachidonoylethanolamide were quantified in ipsilateral cortex of SHR 1 day after stroke induction. The MAGL inhibitor JZL184 significantly increased 2-AG levels in brain but had no effect on N-arachidonoylethanolamide levels ( Figure II in the online-only Data Supplement).
We then examined functional outcome in both vehicle-and JZL184-treated SHR before and on days 1, 3, 7, 14, and 28 after stroke, using the cylinder test that assesses asymmetry in usage of the forelimbs during vertical exploration and the adhesive removal test that assesses sensorimotor performance. In the cylinder test, animals from both groups displayed similar exploratory behavior and spontaneous forelimb usage before induction of stroke. After stroke, vehicle-treated SHR displayed a significant increase in asymmetry of the forelimbs, and this motor deficit was maintained during the entire testing period. On the contrary, JZL184-treated SHR had a substantially improved spontaneous usage of the contralateral forelimb compared with vehicle-treated SHR ( Figure 1C ). In the adhesive removal test, ET-1 induced a contralateral deficit of sensorimotor performance, as evidenced by a significant increase in both time-to-contact and time-to-remove the adhesive tape, which was highest on day 1 and improved gradually with time. Treatment with JZL184 significantly alleviated the
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ET-1-induced contralateral deficit in sensorimotor performance observed in vehicle-treated SHR (P<0.01; Figure 1D ).
JZL184 Decreases Infarct Size and Restores Neurological Deficits After Permanent MCA Occlusion
To further validate the neuroprotective effects of JZL184, we tested its effect on 2 other models of cerebral ischemia, as recommended by the Stroke Therapy Academic Industry Roundtable. 23 The permanent MCA occlusion (MCAO) model, in which the distal part of the left MCA was cauterized, led to a significant and stable reduction of CBF in SHR to ≈23% of baseline and resulted in infarct of both cortical and subcortical areas ( Figure 2A ). In contrast, in WKY, the lesions caused by the permanent MCAO model were limited to the cortex immediately adjacent to the craniotomy ( Figure IIIA in the online-only Data Supplement). We found that the infarct volume after permanent MCAO was significantly smaller Representative cresyl violet-stained coronal sections in SHR (spontaneously hypertensive rats) at 7 days after ET-1-induced stroke (bottom). Infarct volume at 1 day after ET-1-induced stroke in SHR and WKY (Wistar Kyoto). Edema formation as reflected by the brain water content in the ischemic hemispheres of SHR and WKY at 1 day after ET-1-induced stroke. Data are expressed as mean±SEM (n=15 per group for SHR and 7 per group for WKY). **P<0.01 vs vehicle, unpaired t test. C and D, Forelimb asymmetry during spontaneous exploration assessed with cylinder test (C) and sensorimotor deficits measured by adhesive removal test (D) on days 1, 3, 7, 14, and 28 after ET-1-induced stroke in SHR. Data are expressed as mean±SEM (n=15 per group). *P<0.05, **P<0.01 vs the respective vehicle group, 2-way ANOVA followed by Bonferroni multiple comparisons test.
in JZL184-treated SHR than that in vehicle-treated SHR (P<0.01; Figure 2A ). The effect of treatment was functionally relevant because JZL184-treated SHR had significantly better neurological scores than vehicle-treated SHR (P<0.01; Figure 2A ). However, because of the small infarct volume, there were no significant differences in infarct volumes and neurological scores between JZL184-and vehicle-treated WKY ( Figure IIIA in the online-only Data Supplement).
We also studied the effect of JZL184 on the tMCAO model of ischemia/reperfusion in SHR and WKY. In SHR, the tMCAO model led to a significant reduction of CBF (to ≈10% of baseline during the ischemic phase) and resulted in extensive infarcts in both cortical and subcortical areas, as estimated by T2-weighted magnetic resonance imaging and confirmed using standard triphenyltetrazolium chloride staining ( Figure 2B ). Unlike in the ET-1 and the permanent MCAO models of ischemia, however, JZL184 had no effect on ameliorating either infarct volume or functional outcome in SHR subjected to the tMCAO model ( Figure 2B) . Similarly, the differences in infarct volume and functional outcome were not statistically significant between JZL184-and vehicle-treated WKY ( Figure IIIB in the online-only Data Supplement).
Selective MAGL Inhibitor MJN110 Reduces Infarct Volume and Improves Functional Outcomes in Hypertensive Rats
To prove that the neuroprotective properties of JZL184 were specifically related to inhibition of MAGL and not because of unspecific effects, we also tested the more recently synthesized MAGL inhibitor MJN110 24 in SHR after ET-1-induced stroke. We found that the infarct volume in MJN110-treated SHR was significantly smaller than that in vehicle-treated SHR (P<0.01; Figure 3B ). MJN110-treated SHR also had substantially better contralateral forelimb use than vehicletreated controls as measured by the cylinder test, although there were no statistical differences in the forelimb asymmetry at the indicated time points (Figure 3C ). On the other hand, the sensorimotor deficit of the contralateral forelimb caused by the ET-1-induced stroke was significantly less severe in MJN110-treated SHR than in vehicle-treated animals (P<0.01; Figure 3D ). These results indicate that inhibition of MAGL is an effective therapeutical approach to lessen brain damage and improve functional outcome after stroke.
Protective Effects of JZL184 Are Associated With Reduced Neuroinflammation
There is increasing evidence demonstrating the contribution of neuroinflammation to the drastic changes after ischemic stroke. 25 The inflammatory response not only immediately affects the infarcted tissue but also causes long-term damage in peri-infarct regions. To determine whether inhibition of MAGL prevents postischemic neuronal injury, we first stained fixed brain sections with active caspase-3 and neurons in SHR that received JZL184 and observed that active caspase-3 + neurons were distributed both in the infarcted area and in the lesion boundary ( Figure 4A ). The nuclei of these neurons were densely labeled and showed morphological signs of degeneration. We found that the number of active caspase-3 + neurons in JZL184-treated SHR were significantly less than that in vehicle-treated controls 24 hours after ET-1-induced stroke (P<0.05; Figure 4A ).
To investigate whether anti-inflammatory mechanisms are involved in the neuroprotective effects of JZL184, we analyzed expression of proinflammatory mediators and density of Iba-1 + cells in the injured brain. Characteristic components of neuroinflammation, including marked increases in expression of Iba-1 and morphological changes of microglia, occurred in the injured hemisphere of the brain 24 hours after ET-1-induced stroke ( Figure 4B ). Accumulation of amoeboid Iba-1 + cells persisted in the ischemic core and even more in the peri-infarct area 7 days after ET-1-induced stroke. Treatment with JZL184 significantly reduced the overall accumulation of Iba-1 + cells in both ischemic core and peri-infarct regions (P<0.01; Figure 4B ). Considering that accumulation of Iba-1 + cells occurs via multiple mechanisms, including immune cell proliferation and chemoattraction, we determined whether JZL184 affects expression of proinflammatory cytokines and chemokines. The difference in accumulation of Iba-1 + cells was biochemically relevant because JZL184-treated SHR had significantly lower levels of chemokine (C-C motif) ligand 2 (CCL2), CCL3, and CCL5-major chemokines involved in chemoattractant function of immune cells 26 -than vehicletreated SHR (P<0.01; Figure 4C ), indicating that the reduced density of Iba-1 + cells observed after stroke is likely because of the attenuated chemokine-mediated chemotaxis. Similarly, we also observed a significant reduction in the inflammatory cytokine TNF-α (tumor necrosis factor-α; P<0.01; Figure 4C ), suggesting that JZL184 has important immunomodulatory and anti-inflammatory roles in ischemic stroke.
Role of CB1 and CB2 Receptors in the Protective Effect of JZL184
There are 2 well-known cannabinoid receptors, CB1 and CB2, which have been previously considered as therapeutic targets for ischemic stroke. 10 2-AG is a strong agonist to both CB1R and CB2R, and MAGL is the main enzyme responsible for its hydrolysis. 12 We first analyzed expression of CB1 and CB2 in the injured cerebral cortex. Although mRNA expression of CB1 slightly decreased 24 hours and 7 days after ET-1-induced stroke, mRNA expression of CB2 was strongly induced on day 7 after stroke ( Figure IVA in the online-only Data Supplement). In contrast, both CB1 and CB2 mRNA To further investigate the contribution of CB1 and CB2 to the protective effects of JZL184, AM251 (a CB1 antagonist) and AM630 (a CB2 antagonist) were administered before the JZL184 treatment as pharmacological tools. Administration of JZL184 significantly improved stroke outcome in SHR, as shown by a reduction in brain infarction and sensorimotor impairment (P<0.01; Figure 5B ). This effect was partially reversed when SHR were treated with selective CB1 antagonist AM251 ( Figure 5B ). Furthermore, AM251 treatment partially abrogated the JZL184-induced actions on sensorimotor impairment ( Figure 5B) . However, the differences in the infarct volume and functional outcome were not statistically significant ( Figure 5C ). Finally, we also found that the CB2 antagonist AM630 did not alter the JZL184-induced effects on infarct volume ( Figure 5B ) and sensorimotor performance ( Figure 5D ), suggesting that the beneficial effects of MAGL inhibitor might be mediated by reductions in inflammatory response, rather than enhanced action of cannabinoid receptors.
Discussion
In the present study, we investigate the effects of pharmacological inhibition of MAGL in both normotensive and hypertensive rats exposed to 3 different models of ischemic stroke. We show that treatment of the animals with JZL184 or with MJN110 confers a significant amount of neuroprotection by decreasing infarct volume and improving functional outcome in both ET-1 and permanent MCAO models but not in the tMCAO model. We also show that the neuroprotective effects of JZL184 and MJN110 were long-lasting because both inhibitors significantly improved sensorimotor deficits on day 28 after induction of stroke. Indeed, this improvement of functional outcome correlated with both neuroprotective and anti-inflammatory mechanisms in the sensorimotor cortex 
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as evidenced by decreasing apoptotic pathway activation and microglial activation. These results demonstrate that MAGL blockade with JZL184 or with MJN110 significantly reduces brain damage and improves functional outcome and pose MAGL as an important therapeutic target for neuroprotection in ischemic stroke. JZL184 and MJN110 are potent selective inhibitors of MAGL-the primary enzyme responsible for degrading the endocannabinoid 2-AG. 27 They both display high selectivity for MAGL over other brain serine hydrolases, thereby making them useful for studying the effects of endogenous 2-AG. Systemic administration of JZL184 has potent neuroprotective and anti-inflammatory properties in a wide range of neurodegenerative diseases and pathological conditions, including Alzheimer disease, [28] [29] [30] Down syndrome, 31 experimental autoimmune encephalomyelitis, 32 Parkinson disease, 12, 33 and traumatic brain injury. 34 The therapeutic potential of compounds targeting the endocannabinoid system has been extensively investigated and neuroprotective effects have been shown in animal models of cerebral ischemia. 11 Furthermore, because the endocannabinoid system acts on demand with a tightly regulated spatial and temporal selectivity, 35 it may be possible to avoid ubiquitous cannabinoid receptor activation. Thus, it is not surprising to consider MAGL as a potential therapeutic target for improving outcomes of ischemic brain injury. 2-AG and related lipids have been shown to accumulate in a human patient after stroke 4 and in animal models of ischemia. 5 Although in vitro data suggest potent neuroprotective effects of 2-AG, 36, 37 there has been a paucity of in vivo studies, primarily because of the lack of pharmacological agents that selectively target 2-AG metabolism. A previous study has shown a neuroprotective effect of pretreatment with MAGL inhibitor URB602 in neonatal hypoxic-ischemic brain injury in rats. 38 However, the low potency and lack of selectivity for MAGL over fatty acid amid hydrolase has limited the usefulness of that compound.
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JZL184 robustly and selectively enhances 2-AG levels in the brain. 40 Importantly, Nomura et al 12 demonstrated that the neuroprotective effects of JZL184 in the brain are not directly mediated through augmented cannabinoid receptor signaling but rather because of decreased levels of arachidonic acid and its metabolites, such as prostaglandins prostaglandin D2 and prostaglandin E2. Subsequent studies by these researchers revealed that pharmacological inactivation of MAGL with JZL184 significantly reduced the inflammatory response and oxidative stress in a hepatic ischemia/reperfusion injury model. 41 More recent studies have also shown that the neuroprotective effects of JZL184 in acute and chronic animal model of traumatic brain injury and Alzheimer disease are primarily because of a substantial decrease in microglial activation and neuroinflammatory response. 30, 34 Consistent with these anti-inflammatory and neuroprotective effects, we found here that MAGL inhibition with JZL184 significantly protects against ischemic neuronal injury in our rat models of focal ischemia, concordant with suppression of the inflammatory response and microglial activation.
In this study, we used both normotensive and hypertensive rats and 3 different models of experimental ischemia. In normotensive rats, MAGL inhibition proved effective in the ET-1 model (Figure 1 ), but the beneficial trends observed in either permanent occlusion of a distal branch of the MCA or transient occlusion were not statistically significant ( Figure III in the online-only Data Supplement). This could be because of the fact that normotensive rats showed small infarct sizes regardless of whether they were treated or not, making differences harder to detect without testing a much larger number of animals. In hypertensive rats, however, MAGL inhibition proved effective in both ET-1 ( Figure 1 ) and permanent occlusion of a distal branch of the MCA models ( Figure 2A) but not in the tMCAO model ( Figure 2B ). Consistent with our previous report, 15 hypertension negatively influences the stroke outcome in different models of cerebral ischemia and SHR showed larger infarct volumes than WKY in all 3 different ischemia models tested. A major reason for the larger infarct volume is the inadequate collateral circulation in SHR. 42, 43 Adequate collateral circulation provides a compensatory adaptation to arterial occlusion, maintains tissue viability, and offsets infarct growth, suggesting that the collateral circulation is an important defense mechanism that could significantly extend the time window for postischemic treatment. Chronic hypertension impairs the development of collateral vessels in SHR and compromises the ability of the collateral circulation to safeguard regional CBF values within the ischemic region. Indeed, regional CBF in the ischemic region of SHR is not restored to preischemic levels even after reperfusion. 15 Therefore, the lack of adequate collateral circulation in SHR prevents the delivery of neuroprotective treatments to the ischemic region and may explain the lack of response in SHR to MAGL inhibition in the extensive stroke caused by the tMCAO model ( Figure 2B ). Additional studies are needed to determine whether the lack of collateral circulation and reperfusion injury are responsible for the less beneficial effect of MAGL inhibitor observed in SHR after tMCAO.
In conclusion, the results of the present study indicate that pharmacological inhibition of MAGL confers a significant amount of neuroprotection and has long-lasting beneficial effects on functional outcome after ischemic stroke. Even though further investigation is required to elucidate the lipidomic analysis and underlying mechanisms for neuroprotective properties, the well-established effect of JZL184 on MAGL 12 supports the hypothesis that the approach of preventing the degradation of 2-AG can offer a promising therapeutic approach for reducing brain damage after ischemic stroke.
